Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia Severity
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …
Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing ...
Nov 26, 2025 · Teva Pharmaceuticals announced data from the ongoing real-world phase 4 study, coined IMPACT-TD Registry, evaluating the efficacy of deutetrabenazine (Austedo) tablets and its …
Deutetrabenazine Tablets Improve Tardive Dyskinesia Symptoms
Oct 22, 2025 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or deutetrabenazine …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
3 days ago · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …
Teva Pharmaceuticals Reports Positive Real-World Data on AUSTEDO …
Nov 7, 2025 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with …
What is the FDA-Approved Treatment for Tardive Dyskinesia?
Nov 26, 2025 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).
FDA approves new doses of Austedo XR for tardive dyskinesia
Jun 3, 2024 · The FDA has approved Austedo XR in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with Huntington’s disease, according to the manufacturer. …